The investment objective of the scheme is to seek long term capital appreciation by investing in equity/equity related instruments of companies from the healthcare sector. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | -0.07% | 16.57% | N/A | N/A | N/A | 17.69% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | -0.15% | 58.46% | N/A | N/A | N/A | 70.09% |
| Rank within category | 8/19 | 3/18 | 10/18 | 4/18 | 9/17 | 12/14 | 9/12 | N/A | N/A | N/A | N/A |
| Sector Funds | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Yearly returns | N/A | 29.69% | -5.16% | 13.6% |
| Q1 returns | N/A | 7.78% | -10.71% | -5.33% |
| Q2 returns | N/A | 11.82% | 11.85% | 20.72% |
| Q3 returns | N/A | 16.81% | -5.27% | 4.6% |
| Q4 returns | 13.48% | -7.88% | 0.24% | -4.97% |
1% on or before 15D, Nil after 15D
| Alpha | 0.0319102 |
| Beta | 0.965 |
| Sharpe Ratio | 0.227188 |
| Sortino Ratio | 0.477523 |
| R-Squared | 0.6227 |
| Tracking Error | 3.0505 |
| Downside Risk | 22.1192 |
| Std. Deviation (Annualised) | 17.2227 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth Current | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | -7.42% | -6.38% | 5.15% | 4.71% | -0.23% | 15.22% | 11.84% | 12.5% | 11% | 1,511.49 | 2.37 | 0.23 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| TREPS 01-Oct-2026 DEPO 10 | Cash & Cash Equivalents and Net Assets | 26.57% | |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.69% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Derivatives-Futures | 9.63% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.39% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Derivatives-Futures | 9.34% |
| Strides Pharma Science Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.04% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Derivatives-Futures | 8.62% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.37% |
| Alivus Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.21% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.98% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.09% |
| Zydus Wellness Ltd. | Food Products | Domestic Equities | 4.90% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Derivatives-Futures | 4.52% |
| Colgate-Palmolive (India) Ltd. | Personal Products | Domestic Equities | 3.45% |
| Natco Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.01% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.33% |
| 91 Days Treasury Bill 15-Oct-2026 | Treasury Bills | 0.71% | |
| 91 Days Treasury Bill 22-Oct-2026 | Treasury Bills | 0.70% | |
| 91 Days Treasury Bill 05-Nov-2026 | Treasury Bills | 0.70% | |
| 91 Days Treasury Bill 19-Nov-2026 | Treasury Bills | 0.70% | |
| 91 Days Treasury Bill 27-Nov-2026 | Treasury Bills | 0.70% | |
| 91 Days Treasury Bill 03-Dec-2026 | Treasury Bills | 0.70% | |
| 91 Days Treasury Bill 10-Dec-2026 | Treasury Bills | 0.70% | |
| 91 Days Treasury Bill 17-Dec-2026 | Treasury Bills | 0.70% | |
| 91 Days Treasury Bill 24-Dec-2026 | Treasury Bills | 0.70% | |
| LG Electronics India Ltd. | Consumer Durables | Domestic Equities | 0.59% |
| Sumitomo Chemical India Ltd. | Fertilizers & Agrochemicals | Domestic Equities | 0.26% |
| NCA-NET CURRENT ASSETS | Cash & Cash Equivalents and Net Assets | -32.30% | |
| Total | 100.00% | ||
Experience of 8 years in Indian equities and of 3 years in software products. Began his career in core banking software with Infosys Finacle. Began his career in equity research in 2011, picking up the (U.S. based) CFA charter in 2015 and MBA from The Chinese University of Hong Kong in 2017. He won the Thomson Reuters StarMine Award for best stock picker in the IT sector in 2014 and is a lifetime member of the Beta Gamma Sigma honour society.
Sandeep Tandon is the founder of the quant group and has 23 years of experience in the financial services industry. Sandeep’s previous stints include a key role in setting up the equity derivatives desk at ICICI Securities as vice president. He started his career with the Economic Times Research Bureau, a research wing of the leading financial daily of India, The Economic Times. He later joined IDBI Asset Management (now Principal Asset Management), and was part of the core team that initialized asset management, playing a key role in devising, conceptualizing andmarketing one of India’s most successful mutual schemes: IDBI I-NITS 95
Ayusha has been working at quant Mutual Fund as a Research Analyst for the past 15 months, specializing ininvestment research, economics and strategy. Her strong analytical foundation and quantitative expertise have significantly contributed to the fund’s in-depth economic and strategic investment analysis. She has also led engagement initiatives with portfolio companies to inform investment decisions and has effectively utilized data and AI to enhance processes.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
